NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Cogent Biosciences, Inc. (COGT) Stock Analysis

Cogent Biosciences, Inc. (COGT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

COGT

$31.43

+$0.19 (+0.61%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare COGT with… →

COGT Key Statistics

As of Oct 21, 2026
Trading
Open
$31.26
Previous Close
$31.24
Day's Range
31.20–31.94
52-Week Range
13.78–43.73
Volume
2.10M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.31
Valuation
Market Cap
$5.45B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.16
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$328.94M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
173.52M
1-Year Return
+98.17%
Dividend and dates
Earnings Date
November 3, 2026estimated
Avg Volume
1.99M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, COGT closed at $31.43, +98.17% over 1 year.

Cogent Biosciences, Inc. (COGT) has a market capitalization of $5.45B.

In fiscal 2025, COGT reported revenue of $0.00.

COGT Stock Return by Calendar Year

Cogent Biosciences, Inc. (COGT) return since Mar 2018: what $10,000 became

1 year
$10,000 $19,817
+98.17%
5 years
$10,000 $37,551
+275.51%
Since Mar 2018
$10,000 $7,072
−29.28%

If you had invested $10,000 in Cogent Biosciences, Inc. (COGT) at the close on March 29, 2018, the earliest close on record here, it would have been worth $7,072 at the close on October 21, 2026: −29.28% in total, −3.96% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−11.51%
2025+355.38%
2024+32.65%
2023−49.13%
2022+34.73%
2021−23.60%
2020+289.93%
2019−83.64%
2018 (partial year)−60.40%

As of October 21, 2026.

COGT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$328.94M—
2024$0.00−$255.86M—
2023$0.00−$192.41M—
2022$0.00−$140.24M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$333.36M−$328.94M—
2024$0.00—−$275.94M−$255.86M—
2023$0.00—−$208.13M−$192.41M—
2022$0.00—−$147.84M−$140.24M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Cogent Biosciences, Inc. (COGT) carries a market capitalisation of $5.45B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 258.

COGT last closed at $31.43 on October 21, 2026. That is +$0.19 (+0.61%) against the previous close. Over the past 52 weeks the price has ranged from $13.78 to $43.73. The latest close sits 128.08% above that 52-week low.

Financial Health

In fiscal 2025, Cogent Biosciences, Inc. reported revenue of $0.00. The same year closed with a net loss of $328.94M. Trailing earnings per share are −2.16.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the total return is +98.17%. Across 5 years the annualized return works out at +30.29%. The reported beta is 0.31. Daily returns over the trailing 8 years annualize to a volatility of 167.62%.

Growth & Income

The record shows no dividend for COGT.

Across the complete calendar years on file, 2025 returned +355.38% and 2019 returned −83.64%. Of the 7 complete calendar years on file, 4 finished higher. 2026 is still running; the total return is −11.51% year to date.

Peer Comparison

Cogent Biosciences, Inc. (COGT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cogent Biosciences, Inc. COGT $5.45B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Cogent Biosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Cogent Biosciences, Inc.

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.

Visit website →